Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 871–880 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 871
- Medicine slug
- liraglutide
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b898330-eca1-f60a-71d2-b91716e336ed (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (greater than 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2bfc30a-8392-4255-a4d8-fa0b8d1659b2 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (greater than 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35e613e3-7aae-4152-b827-99d1ee7841be (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36f43f-d734-97cc-e063-6294a90ae0da (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2100ec49-57b2-4330-ab5f-057ce9b7e4d0 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a372465-d56b-2b80-e063-6394a90a3304 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0450d8a2-a88e-4849-9788-ed4f5246f223 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (greater than 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14bf9812-14ee-46ce-93b1-686e4906cbbc (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625ac780-70a9-41e4-a892-bcba0f803f1c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (greater than 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36b801-41e2-2eed-e063-6294a90a6f27 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d18f106-0584-4fee-97ab-32771a64b809 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe557ae-4ff0-47a2-8ec3-37bb0fbdcc64 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb032379-043b-443c-d552-b5d25f27f3c4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3946d389-0926-4f77-a708-0acb8153b143 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (greater than 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4253be3b-bda6-4efd-8118-9c9538168a88 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0efc3a89-211a-4496-baab-e8265e07de2b (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb66a46c-9019-4a98-8e5d-581109facfba (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22c86976-9657-4dd0-8fff-0c3f3f08357c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (greater than 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ba917f7-b974-4364-a745-7494ecae3e73 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Liraglutide is extensively bound to plasma protein (>98%).
Projected row 872
- Medicine slug
- liraglutide
- Compared field
- volumeOfDistribution
- Comparison state
- not_comparable
- Reason codes
- DENOMINATOR_MISMATCH
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 0.714286
- Recorded readings
0.07 L/kg
- Numeric value
- 0.07
- Unit
- L/kg
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35e613e3-7aae-4152-b827-99d1ee7841be (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of VICTOZA is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36f43f-d734-97cc-e063-6294a90ae0da (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2100ec49-57b2-4330-ab5f-057ce9b7e4d0 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a372465-d56b-2b80-e063-6394a90a3304 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0450d8a2-a88e-4849-9788-ed4f5246f223 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14bf9812-14ee-46ce-93b1-686e4906cbbc (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a36b801-41e2-2eed-e063-6294a90a6f27 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of VICTOZA is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d18f106-0584-4fee-97ab-32771a64b809 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of VICTOZA is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe557ae-4ff0-47a2-8ec3-37bb0fbdcc64 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb032379-043b-443c-d552-b5d25f27f3c4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4253be3b-bda6-4efd-8118-9c9538168a88 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0efc3a89-211a-4496-baab-e8265e07de2b (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb66a46c-9019-4a98-8e5d-581109facfba (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide injection is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ba917f7-b974-4364-a745-7494ecae3e73 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
The mean volume of distribution after intravenous administration of liraglutide is 0.07 L/kg.
20 to 25 L
- Numeric value
- 20
- Unit
- L
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b898330-eca1-f60a-71d2-b91716e336ed (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is 20 to 25 L (for a person weighing approximately 100 kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2bfc30a-8392-4255-a4d8-fa0b8d1659b2 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is 20 to 25L (for a person weighing approximately 100 kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is 20-25 L (for a person weighing approximately 100 kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:625ac780-70a9-41e4-a892-bcba0f803f1c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is 20 to 25L (for a person weighing approximately 100 kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3946d389-0926-4f77-a708-0acb8153b143 (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is 20 to 25L (for a person weighing approximately 100 kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22c86976-9657-4dd0-8fff-0c3f3f08357c (opens source in a new tab)
Liraglutide label
Version not recorded · Effective date not recorded
Distribution - The mean apparent volume of distribution after subcutaneous administration of liraglutide 3 mg is 20 to 25 L (for a person weighing approximately 100 kg).
Projected row 873
- Medicine slug
- lisdexamfetamine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
8.6 to 9.5 hours
- Numeric value
- 8.6
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c11cb3b6-3dff-477b-a249-b4c3118edc5f (opens source in a new tab)
Lisdexamfetamine label
Version not recorded · Effective date not recorded
The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efbde0f6-b848-4664-b741-c6c630e66108 (opens source in a new tab)
Lisdexamfetamine label
Version not recorded · Effective date not recorded
The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36c40404-fe94-6fb7-e063-6394a90a2657 (opens source in a new tab)
Lisdexamfetamine label
Version not recorded · Effective date not recorded
The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients 6 to 12 years and 10 to 11.3 hours in healthy adults.
Projected row 874
- Medicine slug
- lisdexamfetamine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c11cb3b6-3dff-477b-a249-b4c3118edc5f (opens source in a new tab)
Lisdexamfetamine label
Version not recorded · Effective date not recorded
Absorption Capsule formulation Following single-dose oral administration of lisdexamfetamine dimesylate capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, T max of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efbde0f6-b848-4664-b741-c6c630e66108 (opens source in a new tab)
Lisdexamfetamine label
Version not recorded · Effective date not recorded
Absorption Capsule formulation Following single-dose oral administration of lisdexamfetamine dimesylate capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, T max of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36c40404-fe94-6fb7-e063-6394a90a2657 (opens source in a new tab)
Lisdexamfetamine label
Version not recorded · Effective date not recorded
Absorption Capsule formulation Following single-dose oral administration of lisdexamfetamine dimesylate capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, T max of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively.
Projected row 875
- Medicine slug
- lisinopril
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 160
- Source count
- 159
- Agreement rate
- 1
- Recorded readings
16%
- Numeric value
- 16
- Unit
- %
- Source records
- 159
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 159 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a3d4f6c-9f68-44e4-8cf8-32742e3b5021 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patientswith stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f31909-3cda-4580-adfa-e9992d8c0885 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c008ecb6-970d-4ac9-9402-e21e8d9d76b2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a32db461-4f77-46ef-b49b-250711dade17 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patientswith stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726a6f23-737a-4866-b4ba-b3c18cd2e1ac (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a79a034d-7bbb-4b05-b8fc-8ebf09f33c0c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cd7c59d-ce52-1f5b-e053-2a91aa0a8f86 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa44af9-1aff-314c-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd015c18-1ea6-44e3-9186-8d2f8444d874 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b17cd16b-8d0a-4cfa-bd48-2529983fcd12 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac0c8f1-e3cf-11e6-e053-2a95a90adbcb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f57bd658-05d8-475a-ae74-87d2c7866417 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e297133-669e-4780-a966-c777624e5427 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab561d21-7466-4d8b-8d06-291c1d4d82ff (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b6dc0d4-4acd-3606-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55189717-f5db-9c63-e063-6294a90a6bc9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560513ef-4d2c-8ca0-e063-6394a90a674a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6e4e57-a489-4b36-b093-b93865d3717c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c57e8bc8-ff50-431e-9c1a-384503584d02 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f63c3e0-0b3f-4a04-a592-2ce10dfda202 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33ebf3f2-cd71-4d8b-ac22-1a20a068a13d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9ddfd8-0acc-4fb5-a948-bb2c0cc23a91 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a14eaa6-cb8b-4088-ba15-840b587ab1f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f6bc45e-448e-47f9-9bc4-991b1c503ddf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f678c8-bb66-481e-b42b-1367cbff3169 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:764d51bf-731f-4a37-8e30-e79328cf5a12 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aad4d30-3e18-489c-80ad-ccf7532bb933 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patientswith stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6062fd98-7663-f4b5-e053-2a91aa0acbc3 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17bcc2e-f5ed-4846-95d3-a5479c7fee8d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f49299-7ae5-4d30-86eb-66b739c0e95d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e6364a4-6d66-4151-8197-d45e2a762895 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II to IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5bfa2f-07b8-4f79-8a40-691da006e2ed (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34bb4602-ccff-4939-91b9-26a63bfd40f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e299d477-a612-4af4-b6aa-f5addc8a736d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ec55dd0-9ed5-40d2-978e-9fe773f2281a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f20acd7-2635-4a9b-b732-2a84ea93dea7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e4e69f6-b8a6-462d-a7ec-4cd6636512d0 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6314e49c-8715-2f01-e053-2a91aa0ab2a5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7f5697-acb0-ea95-e053-2991aa0ae7c7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf433cb-bf7d-4b41-9518-400646f9aa2a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06ca101e-4498-4c4e-b455-01915e7ecca0 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1f76fe-816c-384a-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbfa23c2-dae0-4f45-e053-6394a90a4fef (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4c11545-00da-4675-856a-7e600a2f4bd9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faade1f8-f901-40f9-a5a2-2a00e8aa94d1 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47054448-7d5f-43c4-8313-70179a7f9a2e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a35079fa-b693-45e8-9715-488e33e7c1a9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:affd3e43-077e-42e5-a865-c961624bfe93 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d0caa63-9ea2-4a97-a23b-900a7c514bc6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:538429b8-4f10-e825-e063-6294a90a5905 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d32923fe-a323-43c6-af46-bcba7274b0bf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8824e5e5-ed35-4a95-bfd6-98a2e7c4bbce (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f08cfc9-7afc-33aa-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa5d68e7-c2b9-41eb-ade4-2cd57edc1533 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c80515-b26d-5776-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a57d80-6bed-44a3-b3ea-6bb44c34cbfc (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fbefd1-4077-4e81-a0e3-e09fadc48593 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ba2c7d6-bc9e-4d8b-8d1e-c14004750693 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa518e1-d989-1fde-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f22bfb4d-dda6-4c7f-a485-cfb7710ef3de (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6515d800-be95-4a70-ab1e-b4000708dd20 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387068e7-7fb9-44f3-ae1c-e45ebc755a3e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55191baa-f812-2e71-e063-6294a90a8edf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eff766f-82e2-4cd6-e053-2a91aa0a4782 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34953f77-bae1-41fe-af11-3ea0b3ceaa11 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350c6fc9-9774-4d49-9242-19e96944f83b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd3bde1-ee64-126f-e053-6394a90a9b6d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021831ab-dfeb-40fc-aede-4aa1fbb8d918 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c0250c7-ff57-411b-852b-b8e4573f2057 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86e7a336-c416-6fab-e053-2a91aa0a274c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32eb18bc-a80d-4de1-8f38-e591d8f66870 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29e9ac54-f9da-495c-9102-2aac2cc7d88a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf59ff89-a9fa-4fe3-b167-a5d0cba9e438 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9470b102-3c81-469a-a4c5-6816d9d39b07 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3bcfcae-a9ab-4a57-876d-8749ab6c2cff (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc9eb3c-0f54-47b8-b236-8680e0046ea4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae2d9df4-29ce-3d07-e053-2995a90ab184 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f78491-bb4f-7ae7-e053-6394a90aff6f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02c23f9c-f3cf-4366-ae1e-56296f1fedf9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c621c33b-cb67-4ea6-b2bd-96c20a244ea4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f4c1a62-fb84-8cdc-e053-2a91aa0a671a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463308ef-16cb-41d8-8d29-6aae2c5a7b0f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b62815f3-77fc-4074-a28a-918ab5cc32db (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c16edad6-423b-6ff0-e053-2a95a90a0240 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:964c7f28-f62e-30b5-e053-2a95a90ab84c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37aa2542-de44-401b-a6ff-96d2e07914c7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bebf037f-10f8-4e1f-a512-614f81deb891 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9148529f-6278-e507-e053-2995a90aa4cf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d87620e1-1a43-43a2-ab37-b9111ea5c17e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06862c94-103d-4b12-8a74-abf52cb42389 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dbec080-a266-4317-8d4b-b4046206416e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2d493bf-f4d8-4941-8c54-2728d769f6ed (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cced442b-8047-4489-95d6-0700a66fba34 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfd31165-5902-4c94-8fff-2940faa983c1 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db98aaba-5925-f81b-e053-2a95a90a4879 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e09150-22f2-4028-b214-917d686200ad (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eddec313-910c-4bf1-9095-2153db53bc6e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:518a63e3-8ca1-bbd1-e063-6294a90aa524 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6051cc96-86e0-bd0b-e053-2a91aa0a5dcf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33d860a-1e17-45b7-aede-51ab3223bebd (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd804d65-742a-4890-ac9d-bee69968387d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d18f2117-0d2a-4e0d-8ffb-130ca6900364 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1c5b04-b78c-c057-e053-2991aa0aa916 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeee8e9a-333a-416e-ab69-a0d40e146883 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patientswith stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24aab432-9c51-4aee-b9b6-f38816d613bb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af2444f-438c-4ea6-96e8-3dba1af9e1a5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad211de8-d236-48aa-bf27-4501eccfffca (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54dc1e7e-6abd-4f6d-8b41-2b2731d51a65 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5786b8d9-3818-66a5-e053-2991aa0a7025 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50ae0dfe-d961-4bc0-9898-71f69f9a5403 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6292f329-803b-4421-adda-63fad1a0a29f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f68322-f8a1-9011-e053-6394a90a1d2c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbbff4eb-a641-b083-e053-6294a90a404a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3121a4c6-d5c2-4608-a0be-2d9f4b955d5f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2f8ab5-3c87-484a-e053-2995a90a42bb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae2cdf9b-e71e-8315-e053-2995a90a5310 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74415f95-74c9-4329-a6af-a0f165bf7887 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551665a0-9a92-55df-e063-6394a90a1e2e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8a0c806-8f5e-41c0-91c6-ad267af27a53 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03fe066f-c3d7-fa71-e063-6294a90ac6f6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd436b8b-98a6-584c-e053-2995a90ac15d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:971a7e3d-0091-4174-a677-a3f49fe86a0e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8a2a160-0287-41dc-a717-c7fcde7e091f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34ebeea1-6812-4697-84c4-b2ae4f39e55f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab9bc1b4-60cc-76ea-e053-2995a90ac203 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f532f2-c41e-4d1d-989e-7a56b60fbdd4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d81deeaf-7e5e-44c5-9348-5923c4e3ccd6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fa9a16-c112-419f-8d7b-177f580462f2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509a46cf-7a89-b6c0-e063-6394a90a7509 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d16c85-50e2-4d99-afae-6fb902734e42 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b42895-ae25-2d2b-e053-2995a90a899a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e56f3738-3103-3ba4-e053-2a95a90aebb4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:719c4db7-ccbe-4779-baa7-a3c461f3aa52 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patientswith stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5683ac4-59dc-4772-8bc6-984c698afbeb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cce5bcc0-2e38-41d8-a41e-4f4ea83e6248 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03a497fe-fb09-4b2c-8ee0-2019600192b8 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:705582ed-da8c-418f-8bb2-fc0b74ed0a88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a83bbc-9871-4df8-b3f2-7aba5149f3fe (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59fd2167-4da4-9143-83bd-3b6aa5051511 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6c31e2-b5a4-4279-8013-a8dad37ea73b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b5a2c0-6ad2-48e7-9ffe-715d9159f389 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12d6fe7e-b5a2-4d49-9a06-a6150234d061 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bc69836-a659-4e3b-84a7-a00b7c4dc268 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:176c744a-d4e3-4a4b-ac62-4fbcb1d8d7bf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b14778-a57e-51d5-e053-2a95a90a9aad (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b29545-6ba5-6bf5-e053-2995a90ae7de (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a881df2d-e3b7-413f-b4bb-2c3d917b0811 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:051375d4-7d38-45b3-9ca4-f2cd1f527b1b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3783ab4c-2bed-414e-8927-62d47e3e3496 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c55efa-36bd-4613-98ca-2eb589a31e53 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II to Class IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95376981-4620-c9aa-e053-2995a90a1390 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a589a9-acc2-bfbe-e053-2995a90a0bd2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba3610b-de5c-fa33-e053-2a95a90acbc5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0b068b4-1e55-446b-912b-3534e9e6fb75 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:babb75f0-bccc-44e8-955a-6873344ccc21 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b0555e-41d2-44c3-b27b-ad5d701378dc (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3451292b-7867-4dc2-afaa-da66b4016017 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43e2c8d1-3704-4323-bcaf-f582572b81f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class II-IV congestive heart failure, and the volume of distribution appears to be slightly smaller than that in normal subjects.
Projected row 876
- Medicine slug
- lisinopril
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 160
- Source count
- 160
- Agreement rate
- 1
- Recorded readings
12 hours
- Numeric value
- 12
- Unit
- hours
- Source records
- 160
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 160 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a3d4f6c-9f68-44e4-8cf8-32742e3b5021 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.Lisinopril does not appear to be bound to other serum proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f31909-3cda-4580-adfa-e9992d8c0885 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c008ecb6-970d-4ac9-9402-e21e8d9d76b2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a32db461-4f77-46ef-b49b-250711dade17 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.Lisinopril does not appear to be bound to other serum proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726a6f23-737a-4866-b4ba-b3c18cd2e1ac (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a79a034d-7bbb-4b05-b8fc-8ebf09f33c0c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cd7c59d-ce52-1f5b-e053-2a91aa0a8f86 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa44af9-1aff-314c-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd015c18-1ea6-44e3-9186-8d2f8444d874 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b17cd16b-8d0a-4cfa-bd48-2529983fcd12 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac0c8f1-e3cf-11e6-e053-2a95a90adbcb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f57bd658-05d8-475a-ae74-87d2c7866417 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e297133-669e-4780-a966-c777624e5427 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab561d21-7466-4d8b-8d06-291c1d4d82ff (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b6dc0d4-4acd-3606-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55189717-f5db-9c63-e063-6294a90a6bc9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560513ef-4d2c-8ca0-e063-6394a90a674a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6e4e57-a489-4b36-b093-b93865d3717c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c57e8bc8-ff50-431e-9c1a-384503584d02 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f63c3e0-0b3f-4a04-a592-2ce10dfda202 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33ebf3f2-cd71-4d8b-ac22-1a20a068a13d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9ddfd8-0acc-4fb5-a948-bb2c0cc23a91 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a14eaa6-cb8b-4088-ba15-840b587ab1f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f6bc45e-448e-47f9-9bc4-991b1c503ddf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f678c8-bb66-481e-b42b-1367cbff3169 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:764d51bf-731f-4a37-8e30-e79328cf5a12 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aad4d30-3e18-489c-80ad-ccf7532bb933 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.Lisinopril does not appear to be bound to other serum proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6062fd98-7663-f4b5-e053-2a91aa0acbc3 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17bcc2e-f5ed-4846-95d3-a5479c7fee8d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f49299-7ae5-4d30-86eb-66b739c0e95d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e6364a4-6d66-4151-8197-d45e2a762895 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5bfa2f-07b8-4f79-8a40-691da006e2ed (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34bb4602-ccff-4939-91b9-26a63bfd40f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e299d477-a612-4af4-b6aa-f5addc8a736d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ec55dd0-9ed5-40d2-978e-9fe773f2281a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f20acd7-2635-4a9b-b732-2a84ea93dea7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e4e69f6-b8a6-462d-a7ec-4cd6636512d0 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6314e49c-8715-2f01-e053-2a91aa0ab2a5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7f5697-acb0-ea95-e053-2991aa0ae7c7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf433cb-bf7d-4b41-9518-400646f9aa2a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06ca101e-4498-4c4e-b455-01915e7ecca0 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1f76fe-816c-384a-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbfa23c2-dae0-4f45-e053-6394a90a4fef (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4c11545-00da-4675-856a-7e600a2f4bd9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faade1f8-f901-40f9-a5a2-2a00e8aa94d1 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47054448-7d5f-43c4-8313-70179a7f9a2e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a35079fa-b693-45e8-9715-488e33e7c1a9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:affd3e43-077e-42e5-a865-c961624bfe93 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d0caa63-9ea2-4a97-a23b-900a7c514bc6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:538429b8-4f10-e825-e063-6294a90a5905 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d32923fe-a323-43c6-af46-bcba7274b0bf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8824e5e5-ed35-4a95-bfd6-98a2e7c4bbce (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f08cfc9-7afc-33aa-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa5d68e7-c2b9-41eb-ade4-2cd57edc1533 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c80515-b26d-5776-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a57d80-6bed-44a3-b3ea-6bb44c34cbfc (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fbefd1-4077-4e81-a0e3-e09fadc48593 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ba2c7d6-bc9e-4d8b-8d1e-c14004750693 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa518e1-d989-1fde-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f22bfb4d-dda6-4c7f-a485-cfb7710ef3de (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6515d800-be95-4a70-ab1e-b4000708dd20 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387068e7-7fb9-44f3-ae1c-e45ebc755a3e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55191baa-f812-2e71-e063-6294a90a8edf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eff766f-82e2-4cd6-e053-2a91aa0a4782 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34953f77-bae1-41fe-af11-3ea0b3ceaa11 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350c6fc9-9774-4d49-9242-19e96944f83b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd3bde1-ee64-126f-e053-6394a90a9b6d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021831ab-dfeb-40fc-aede-4aa1fbb8d918 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c0250c7-ff57-411b-852b-b8e4573f2057 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86e7a336-c416-6fab-e053-2a91aa0a274c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32eb18bc-a80d-4de1-8f38-e591d8f66870 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29e9ac54-f9da-495c-9102-2aac2cc7d88a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf59ff89-a9fa-4fe3-b167-a5d0cba9e438 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9470b102-3c81-469a-a4c5-6816d9d39b07 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3bcfcae-a9ab-4a57-876d-8749ab6c2cff (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc9eb3c-0f54-47b8-b236-8680e0046ea4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae2d9df4-29ce-3d07-e053-2995a90ab184 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f78491-bb4f-7ae7-e053-6394a90aff6f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02c23f9c-f3cf-4366-ae1e-56296f1fedf9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c621c33b-cb67-4ea6-b2bd-96c20a244ea4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f4c1a62-fb84-8cdc-e053-2a91aa0a671a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463308ef-16cb-41d8-8d29-6aae2c5a7b0f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b62815f3-77fc-4074-a28a-918ab5cc32db (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c16edad6-423b-6ff0-e053-2a95a90a0240 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:964c7f28-f62e-30b5-e053-2a95a90ab84c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37aa2542-de44-401b-a6ff-96d2e07914c7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bebf037f-10f8-4e1f-a512-614f81deb891 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9148529f-6278-e507-e053-2995a90aa4cf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d87620e1-1a43-43a2-ab37-b9111ea5c17e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06862c94-103d-4b12-8a74-abf52cb42389 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dbec080-a266-4317-8d4b-b4046206416e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2d493bf-f4d8-4941-8c54-2728d769f6ed (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cced442b-8047-4489-95d6-0700a66fba34 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfd31165-5902-4c94-8fff-2940faa983c1 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db98aaba-5925-f81b-e053-2a95a90a4879 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e09150-22f2-4028-b214-917d686200ad (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eddec313-910c-4bf1-9095-2153db53bc6e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:518a63e3-8ca1-bbd1-e063-6294a90aa524 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6051cc96-86e0-bd0b-e053-2a91aa0a5dcf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33d860a-1e17-45b7-aede-51ab3223bebd (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd804d65-742a-4890-ac9d-bee69968387d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5db9549-e179-3db6-e053-2995a90a1544 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d18f2117-0d2a-4e0d-8ffb-130ca6900364 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1c5b04-b78c-c057-e053-2991aa0aa916 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeee8e9a-333a-416e-ab69-a0d40e146883 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.Lisinopril does not appear to be bound to other serum proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24aab432-9c51-4aee-b9b6-f38816d613bb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af2444f-438c-4ea6-96e8-3dba1af9e1a5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad211de8-d236-48aa-bf27-4501eccfffca (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54dc1e7e-6abd-4f6d-8b41-2b2731d51a65 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5786b8d9-3818-66a5-e053-2991aa0a7025 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50ae0dfe-d961-4bc0-9898-71f69f9a5403 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6292f329-803b-4421-adda-63fad1a0a29f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f68322-f8a1-9011-e053-6394a90a1d2c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbbff4eb-a641-b083-e053-6294a90a404a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3121a4c6-d5c2-4608-a0be-2d9f4b955d5f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2f8ab5-3c87-484a-e053-2995a90a42bb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae2cdf9b-e71e-8315-e053-2995a90a5310 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74415f95-74c9-4329-a6af-a0f165bf7887 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551665a0-9a92-55df-e063-6394a90a1e2e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8a0c806-8f5e-41c0-91c6-ad267af27a53 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03fe066f-c3d7-fa71-e063-6294a90ac6f6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd436b8b-98a6-584c-e053-2995a90ac15d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:971a7e3d-0091-4174-a677-a3f49fe86a0e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8a2a160-0287-41dc-a717-c7fcde7e091f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34ebeea1-6812-4697-84c4-b2ae4f39e55f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab9bc1b4-60cc-76ea-e053-2995a90ac203 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f532f2-c41e-4d1d-989e-7a56b60fbdd4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d81deeaf-7e5e-44c5-9348-5923c4e3ccd6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fa9a16-c112-419f-8d7b-177f580462f2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509a46cf-7a89-b6c0-e063-6394a90a7509 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d16c85-50e2-4d99-afae-6fb902734e42 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b42895-ae25-2d2b-e053-2995a90a899a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e56f3738-3103-3ba4-e053-2a95a90aebb4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:719c4db7-ccbe-4779-baa7-a3c461f3aa52 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.Lisinopril does not appear to be bound to other serum proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5683ac4-59dc-4772-8bc6-984c698afbeb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cce5bcc0-2e38-41d8-a41e-4f4ea83e6248 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03a497fe-fb09-4b2c-8ee0-2019600192b8 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:705582ed-da8c-418f-8bb2-fc0b74ed0a88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a83bbc-9871-4df8-b3f2-7aba5149f3fe (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59fd2167-4da4-9143-83bd-3b6aa5051511 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6c31e2-b5a4-4279-8013-a8dad37ea73b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b5a2c0-6ad2-48e7-9ffe-715d9159f389 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12d6fe7e-b5a2-4d49-9a06-a6150234d061 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bc69836-a659-4e3b-84a7-a00b7c4dc268 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:176c744a-d4e3-4a4b-ac62-4fbcb1d8d7bf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b14778-a57e-51d5-e053-2a95a90a9aad (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b29545-6ba5-6bf5-e053-2995a90ae7de (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a881df2d-e3b7-413f-b4bb-2c3d917b0811 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:051375d4-7d38-45b3-9ca4-f2cd1f527b1b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3783ab4c-2bed-414e-8927-62d47e3e3496 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c55efa-36bd-4613-98ca-2eb589a31e53 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95376981-4620-c9aa-e053-2995a90a1390 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a589a9-acc2-bfbe-e053-2995a90a0bd2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba3610b-de5c-fa33-e053-2a95a90acbc5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0b068b4-1e55-446b-912b-3534e9e6fb75 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:babb75f0-bccc-44e8-955a-6873344ccc21 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b0555e-41d2-44c3-b27b-ad5d701378dc (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3451292b-7867-4dc2-afaa-da66b4016017 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43e2c8d1-3704-4323-bcaf-f582572b81f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours.
Projected row 877
- Medicine slug
- lisinopril
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 160
- Source count
- 160
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 160
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 160 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a3d4f6c-9f68-44e4-8cf8-32742e3b5021 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After dosesof 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f31909-3cda-4580-adfa-e9992d8c0885 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c008ecb6-970d-4ac9-9402-e21e8d9d76b2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a32db461-4f77-46ef-b49b-250711dade17 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After dosesof 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726a6f23-737a-4866-b4ba-b3c18cd2e1ac (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a79a034d-7bbb-4b05-b8fc-8ebf09f33c0c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cd7c59d-ce52-1f5b-e053-2a91aa0a8f86 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa44af9-1aff-314c-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd015c18-1ea6-44e3-9186-8d2f8444d874 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b17cd16b-8d0a-4cfa-bd48-2529983fcd12 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac0c8f1-e3cf-11e6-e053-2a95a90adbcb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f57bd658-05d8-475a-ae74-87d2c7866417 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e297133-669e-4780-a966-c777624e5427 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab561d21-7466-4d8b-8d06-291c1d4d82ff (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b6dc0d4-4acd-3606-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55189717-f5db-9c63-e063-6294a90a6bc9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:560513ef-4d2c-8ca0-e063-6394a90a674a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6e4e57-a489-4b36-b093-b93865d3717c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c57e8bc8-ff50-431e-9c1a-384503584d02 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f63c3e0-0b3f-4a04-a592-2ce10dfda202 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33ebf3f2-cd71-4d8b-ac22-1a20a068a13d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9ddfd8-0acc-4fb5-a948-bb2c0cc23a91 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a14eaa6-cb8b-4088-ba15-840b587ab1f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f6bc45e-448e-47f9-9bc4-991b1c503ddf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f678c8-bb66-481e-b42b-1367cbff3169 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:764d51bf-731f-4a37-8e30-e79328cf5a12 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aad4d30-3e18-489c-80ad-ccf7532bb933 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After dosesof 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6062fd98-7663-f4b5-e053-2a91aa0acbc3 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17bcc2e-f5ed-4846-95d3-a5479c7fee8d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42f49299-7ae5-4d30-86eb-66b739c0e95d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e6364a4-6d66-4151-8197-d45e2a762895 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5bfa2f-07b8-4f79-8a40-691da006e2ed (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34bb4602-ccff-4939-91b9-26a63bfd40f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e299d477-a612-4af4-b6aa-f5addc8a736d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ec55dd0-9ed5-40d2-978e-9fe773f2281a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f20acd7-2635-4a9b-b732-2a84ea93dea7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e4e69f6-b8a6-462d-a7ec-4cd6636512d0 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6314e49c-8715-2f01-e053-2a91aa0ab2a5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7f5697-acb0-ea95-e053-2991aa0ae7c7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf433cb-bf7d-4b41-9518-400646f9aa2a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06ca101e-4498-4c4e-b455-01915e7ecca0 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1f76fe-816c-384a-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbfa23c2-dae0-4f45-e053-6394a90a4fef (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4c11545-00da-4675-856a-7e600a2f4bd9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:faade1f8-f901-40f9-a5a2-2a00e8aa94d1 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47054448-7d5f-43c4-8313-70179a7f9a2e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a35079fa-b693-45e8-9715-488e33e7c1a9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:affd3e43-077e-42e5-a865-c961624bfe93 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d0caa63-9ea2-4a97-a23b-900a7c514bc6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:538429b8-4f10-e825-e063-6294a90a5905 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d32923fe-a323-43c6-af46-bcba7274b0bf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8824e5e5-ed35-4a95-bfd6-98a2e7c4bbce (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f08cfc9-7afc-33aa-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa5d68e7-c2b9-41eb-ade4-2cd57edc1533 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c80515-b26d-5776-e054-00144ff8d46c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a57d80-6bed-44a3-b3ea-6bb44c34cbfc (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5fbefd1-4077-4e81-a0e3-e09fadc48593 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ba2c7d6-bc9e-4d8b-8d1e-c14004750693 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa518e1-d989-1fde-e054-00144ff88e88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f22bfb4d-dda6-4c7f-a485-cfb7710ef3de (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6515d800-be95-4a70-ab1e-b4000708dd20 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387068e7-7fb9-44f3-ae1c-e45ebc755a3e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55191baa-f812-2e71-e063-6294a90a8edf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eff766f-82e2-4cd6-e053-2a91aa0a4782 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34953f77-bae1-41fe-af11-3ea0b3ceaa11 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350c6fc9-9774-4d49-9242-19e96944f83b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd3bde1-ee64-126f-e053-6394a90a9b6d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021831ab-dfeb-40fc-aede-4aa1fbb8d918 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c0250c7-ff57-411b-852b-b8e4573f2057 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86e7a336-c416-6fab-e053-2a91aa0a274c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32eb18bc-a80d-4de1-8f38-e591d8f66870 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29e9ac54-f9da-495c-9102-2aac2cc7d88a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf59ff89-a9fa-4fe3-b167-a5d0cba9e438 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9470b102-3c81-469a-a4c5-6816d9d39b07 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3bcfcae-a9ab-4a57-876d-8749ab6c2cff (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc9eb3c-0f54-47b8-b236-8680e0046ea4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae2d9df4-29ce-3d07-e053-2995a90ab184 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7f78491-bb4f-7ae7-e053-6394a90aff6f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02c23f9c-f3cf-4366-ae1e-56296f1fedf9 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c621c33b-cb67-4ea6-b2bd-96c20a244ea4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f4c1a62-fb84-8cdc-e053-2a91aa0a671a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463308ef-16cb-41d8-8d29-6aae2c5a7b0f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b62815f3-77fc-4074-a28a-918ab5cc32db (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c16edad6-423b-6ff0-e053-2a95a90a0240 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:964c7f28-f62e-30b5-e053-2a95a90ab84c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37aa2542-de44-401b-a6ff-96d2e07914c7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bebf037f-10f8-4e1f-a512-614f81deb891 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9148529f-6278-e507-e053-2995a90aa4cf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d87620e1-1a43-43a2-ab37-b9111ea5c17e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06862c94-103d-4b12-8a74-abf52cb42389 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dbec080-a266-4317-8d4b-b4046206416e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2d493bf-f4d8-4941-8c54-2728d769f6ed (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cced442b-8047-4489-95d6-0700a66fba34 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfd31165-5902-4c94-8fff-2940faa983c1 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db98aaba-5925-f81b-e053-2a95a90a4879 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e09150-22f2-4028-b214-917d686200ad (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eddec313-910c-4bf1-9095-2153db53bc6e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:518a63e3-8ca1-bbd1-e063-6294a90aa524 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6051cc96-86e0-bd0b-e053-2a91aa0a5dcf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33d860a-1e17-45b7-aede-51ab3223bebd (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd804d65-742a-4890-ac9d-bee69968387d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5db9549-e179-3db6-e053-2995a90a1544 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d18f2117-0d2a-4e0d-8ffb-130ca6900364 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1c5b04-b78c-c057-e053-2991aa0aa916 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeee8e9a-333a-416e-ab69-a0d40e146883 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After dosesof 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24aab432-9c51-4aee-b9b6-f38816d613bb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af2444f-438c-4ea6-96e8-3dba1af9e1a5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad211de8-d236-48aa-bf27-4501eccfffca (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54dc1e7e-6abd-4f6d-8b41-2b2731d51a65 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5786b8d9-3818-66a5-e053-2991aa0a7025 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50ae0dfe-d961-4bc0-9898-71f69f9a5403 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6292f329-803b-4421-adda-63fad1a0a29f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f68322-f8a1-9011-e053-6394a90a1d2c (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbbff4eb-a641-b083-e053-6294a90a404a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3121a4c6-d5c2-4608-a0be-2d9f4b955d5f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2f8ab5-3c87-484a-e053-2995a90a42bb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae2cdf9b-e71e-8315-e053-2995a90a5310 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74415f95-74c9-4329-a6af-a0f165bf7887 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551665a0-9a92-55df-e063-6394a90a1e2e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8a0c806-8f5e-41c0-91c6-ad267af27a53 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03fe066f-c3d7-fa71-e063-6294a90ac6f6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd436b8b-98a6-584c-e053-2995a90ac15d (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:971a7e3d-0091-4174-a677-a3f49fe86a0e (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8a2a160-0287-41dc-a717-c7fcde7e091f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34ebeea1-6812-4697-84c4-b2ae4f39e55f (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab9bc1b4-60cc-76ea-e053-2995a90ac203 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24f532f2-c41e-4d1d-989e-7a56b60fbdd4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d81deeaf-7e5e-44c5-9348-5923c4e3ccd6 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fa9a16-c112-419f-8d7b-177f580462f2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509a46cf-7a89-b6c0-e063-6394a90a7509 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d16c85-50e2-4d99-afae-6fb902734e42 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b42895-ae25-2d2b-e053-2995a90a899a (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e56f3738-3103-3ba4-e053-2a95a90aebb4 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:719c4db7-ccbe-4779-baa7-a3c461f3aa52 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After dosesof 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5683ac4-59dc-4772-8bc6-984c698afbeb (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cce5bcc0-2e38-41d8-a41e-4f4ea83e6248 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03a497fe-fb09-4b2c-8ee0-2019600192b8 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:705582ed-da8c-418f-8bb2-fc0b74ed0a88 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a83bbc-9871-4df8-b3f2-7aba5149f3fe (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59fd2167-4da4-9143-83bd-3b6aa5051511 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d6c31e2-b5a4-4279-8013-a8dad37ea73b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b5a2c0-6ad2-48e7-9ffe-715d9159f389 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12d6fe7e-b5a2-4d49-9a06-a6150234d061 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bc69836-a659-4e3b-84a7-a00b7c4dc268 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:176c744a-d4e3-4a4b-ac62-4fbcb1d8d7bf (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b14778-a57e-51d5-e053-2a95a90a9aad (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b29545-6ba5-6bf5-e053-2995a90ae7de (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a881df2d-e3b7-413f-b4bb-2c3d917b0811 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:051375d4-7d38-45b3-9ca4-f2cd1f527b1b (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3783ab4c-2bed-414e-8927-62d47e3e3496 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6c55efa-36bd-4613-98ca-2eb589a31e53 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95376981-4620-c9aa-e053-2995a90a1390 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a589a9-acc2-bfbe-e053-2995a90a0bd2 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ba3610b-de5c-fa33-e053-2a95a90acbc5 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0b068b4-1e55-446b-912b-3534e9e6fb75 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:babb75f0-bccc-44e8-955a-6873344ccc21 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b0555e-41d2-44c3-b27b-ad5d701378dc (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3451292b-7867-4dc2-afaa-da66b4016017 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43e2c8d1-3704-4323-bcaf-f582572b81f7 (opens source in a new tab)
Lisinopril label
Version not recorded · Effective date not recorded
After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%.
Projected row 878
- Medicine slug
- lithium
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 0.833333
- Recorded readings
18 to 36 hours
- Numeric value
- 18
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be1346df-4a39-45e8-874b-e2a496847fd5 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
The elimination half-life of lithium is approximately 18 to 36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677b20c4-84f0-4716-aca3-aead3bbe1283 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
The elimination half-life of lithium is approximately 18 to 36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a12d50fb-2c2f-4105-ad17-adbf90d439d4 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
The elimination half-life of lithium is approximately 18 to 36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9baf45-830f-4a8a-8986-5caeaa1b38cf (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
The elimination half-life of lithium is approximately 18 to 36 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d0e8e3-bc0b-0cc1-e063-6394a90a0a6d (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
The elimination half-life of lithium is approximately 18 to 36 hours.
18 hours
- Numeric value
- 18
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e95036c7-542a-437a-969b-f95f6f949f84 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
The elimination half-life of lithium is approximately 18 hours to 36 hours.
Projected row 879
- Medicine slug
- lithium
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 0.833333
- Recorded readings
0.25 to 3 hours
- Numeric value
- 0.25
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be1346df-4a39-45e8-874b-e2a496847fd5 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
Peak serum concentrations (T max ) occur 0.25 to 3 hours after oral administration of immediate release preparations and 2 to 6 hours after sustained-release preparations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677b20c4-84f0-4716-aca3-aead3bbe1283 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
Peak serum concentrations (T max ) occur 0.25 to 3 hours after oral administration of immediate release preparations and 2 to 6 hours after sustained-release preparations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a12d50fb-2c2f-4105-ad17-adbf90d439d4 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
Peak serum concentrations (T max ) occur 0.25 to 3 hours after oral administration of immediate release preparations and 2 to 6 hours after sustained-release preparations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9baf45-830f-4a8a-8986-5caeaa1b38cf (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
Peak serum concentrations (T max ) occur 0.25 to 3 hours after oral administration of immediate release preparations and 2 to 6 hours after sustained-release preparations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d0e8e3-bc0b-0cc1-e063-6394a90a0a6d (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
Peak serum concentrations (T max ) occur 0.25 to 3 hours after oral administration of immediate release preparations and 2 to 6 hours after sustained-release preparations.
0.25 hour
- Numeric value
- 0.25
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e95036c7-542a-437a-969b-f95f6f949f84 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
Peak serum concentrations (T max ) occur 0.25 hour to 3 hours after oral administration of immediate release preparations and 2 hours to 6 hours after sustained-release preparations.
Projected row 880
- Medicine slug
- lithium
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 6
- Source count
- 5
- Agreement rate
- 0.8
- Recorded readings
0.7 to 1 L/kg
- Numeric value
- 0.7
- Unit
- L/kg
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be1346df-4a39-45e8-874b-e2a496847fd5 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
After equilibrium, the apparent volume of distribution is 0.7 to 1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:677b20c4-84f0-4716-aca3-aead3bbe1283 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
After equilibrium, the apparent volume of distribution is 0.7 to 1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff9baf45-830f-4a8a-8986-5caeaa1b38cf (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
After equilibrium, the apparent volume of distribution is 0.7 to 1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59d0e8e3-bc0b-0cc1-e063-6394a90a0a6d (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
After equilibrium, the apparent volume of distribution is 0.7 to 1 L/kg.
0.7 L/kg
- Numeric value
- 0.7
- Unit
- L/kg
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e95036c7-542a-437a-969b-f95f6f949f84 (opens source in a new tab)
Lithium label
Version not recorded · Effective date not recorded
After equilibrium, the apparent volume of distribution is 0.7 L/kg to 1 L/kg.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=870Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.